7th IPF Summit
Now in its 7th year, this is the undisputed (and only!) meeting dedicated to harnessing emerging biological understanding, employing novel preclinical models to cement translational confidence and capturing imaging endpoints to develop and advance IPF therapeutics to patients in need.
7th IPF Summit
View agenda here
What’s new and unmissable for 2023?
- A pre-conference seminar day with three tracks of content: Emerging Biology, Translational, and Clinical
- 31 new world-class speakers alongside returning KOLs including Toby Maher, Fernando Martinez, Gisli Jenkins, Naftali Kaminski and Joyce Lee
- A brand-new Ambassador Evening for attendees to unite at the start of the conference and network with the community working to bring life-changing therapeutics forward
- Exclusive presentations on phase 2 and 3 updates from senior decision makers at Bristol Myers Squibb, Pliant Therapeutics, FibroGen, Galecto and Vicore
See what's on in the full agenda here.
Join your peers and key opinion leaders in person and take away critical insights at the only dedicated IPF meeting. Already confirmed attendees include Boehringer Ingelheim, Genentech, Astrazeneca, Pfizer, Bristol Myers Squibb, AbbVie, Pliant Therapeutics, FibroGen, Galecto, Vicore and many more; be a part of the conversation and join us this September to maximise the therapeutic and commercial opportunities at your fingertips.
From illuminating the underlying disease pathobiology and cross-talk to accelerating the translation of novel therapeutics into the clinic with precision medicine to harnessing imaging endpoints in clinical trial design, this year’s agenda covers everything from bench to bedside and will not be one for your team to miss.
